Results 101 to 110 of about 35,534 (303)

MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2

Journal of Experimental & Clinical Cancer Research, 2019
Background The MYCN amplification is a defining hallmark of high-risk neuroblastoma. Due to irregular oncogenes orchestration, tumor cells exhibit distinct fatty acid metabolic features from non-tumor cells. However, the function of MYCN in neuroblastoma
Yi Ding, Jie Yang, Yawen Ma, Tengteng Yao, Xingyu Chen, Shengfang Ge, Lihua Wang, Xianqun Fan   +7 more
doaj   +1 more source

The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression

Journal of Experimental & Clinical Cancer Research, 2020
Background The oncogene MYCN is critical for tumorigenesis of several types of cancers including neuroblastoma. We previously reported that miR-506-3p repressed MYCN expression in neuroblastoma cells. However, the mechanism underlying such regulation was
Zhenze Zhao, Spencer D. Shelton, Alejandro Oviedo, Amy L. Baker, Collin P. Bryant, Soroush Omidvarnia, Liqin Du   +6 more
doaj   +1 more source

Topotecan-vincristine-doxorubicin in stage 4 high risk neuroblastoma patients failing to achieve a complete metastatic response to rapid COJEC : a SIOPEN study [PDF]

, 2018
Purpose : Metastatic response to induction therapy for high-risk neuroblastoma is a prognostic factor. In the International Society of Paediatric Oncology Europe Neuroblastoma (SIOPEN) HR-NBL-1 protocol, only patients with metastatic complete response ...
Amoroso, L, Brock, P, Castel, V, Erminio, G, Garaventa, A, Grp, Siopen, Haupt, R, Ladenstein, R, Laureys, G, Luksch, R, Makin, G, Pasquet, M, Pearson, A. D. J, Thomas, C, Valteau-Couanet, D   +14 more
core   +2 more sources

Targeting PRKCN, an Essential Driver Orchestrating mTOR‐IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma

Advanced Science, EarlyView.
Constitutive PRKCN expression is driven by super‐enhancers and modulated by NF‐κB signaling in multiple myeloma (MM). PRKCN activates mTORC1/2‐IRF4 signaling axis and favors tumor cell growth independently of its kinase activity. IRF4 reciprocally promotes PRKCN transcription, creating a feed‐forward loop.
Koukou Tang, Dongpeng Jiang, Peng Ke, Xiaosen Bian, Lili Zhang, Ying Zhang, Tingting Zhu, Weiwei Qu, Wenhui Qi, Yang Xu, Chengcheng Fu, Depei Wu, Jianhong Chu   +12 more
wiley   +1 more source

HLXB9 gene expression, and nuclear location during in vitro neuronal differentiation in the SK-N-BE neuroblastoma cell line [PDF]

, 2014
Copyright @ 2014 Leotta et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source ...
Brundo, MV, Federico, C, Leotta, CG, Saccone, S, Tosi, S   +4 more
core   +1 more source

A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors

Oncogene, 2021
MYCN drives aggressive behavior and refractoriness to chemotherapy, in several tumors. Since MYCN inactivation in clinical settings is not achievable, alternative vulnerabilities of MYCN-driven tumors need to be explored to identify more effective and ...
Stefano Di Giulio, V. Colicchia, F. Pastorino, F. Pedretti, F. Fabretti, Vittoria Nicolis di Robilant, Valentina Ramponi, Giorgia Scafetta, M. Moretti, V. Licursi, F. Belardinilli, G. Peruzzi, Paola Infante, B. Goffredo, A. Coppa, G. Canettieri, A. Bartolazzi, M. Ponzoni, G. Giannini, M. Petroni   +19 more
semanticscholar   +1 more source

Advanced extracellular vesicle immunotherapy

FlexMat, EarlyView.
A diagrammatic depiction of the therapeutic applicability of extracellular vesicles (EVs) in immunotherapy. This review explores the dual roles of tumor‐derived and immune cell‐derived EVs in cancer immunotherapy, discusses recent progress in EV engineering that improve their clinical utility, and evaluates their potential to augment existing ...
Jingjing Zhang, Yunfei Mu, Xianyue Ji, Xiaoting Jiang, Ruiheng Wang, Xianguang Ding, Lianhui Wang   +6 more
wiley   +1 more source

KAP1 stabilizes MYCN mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA m6A reader YTHDC1 protein degradation

Journal of Experimental & Clinical Cancer Research
Background Neuroblastoma (NB) patients with amplified MYCN often face a grim prognosis and are resistant to existing therapies, yet MYCN protein is considered undruggable.
Yi Yang, Yingwen Zhang, Guoyu Chen, Bowen Sun, Fei Luo, Yijin Gao, Haizhong Feng, Yanxin Li   +7 more
doaj   +1 more source

Adult Pulmonary Blastoma: A Case Report with Spectrum of Rare Manifestations [PDF]

Türk Patoloji Dergisi
Pulmonary blastoma (PB) is an exceedingly rare and aggressive malignant lung neoplasm that has distinct biphasic morphology. In this report, we document rare manifestations and molecular alterations in PB.
Mayur PARKHI, Nishtha AHUJA, Divyesh KUMAR, Rajender Kumar BASHER, Navneet SINGH, Harkant SINGH, Amanjit BAL   +6 more
doaj   +1 more source

DREAM target reactivation by core transcriptional regulators supports neuroblastoma growth

Molecular & Cellular Oncology, 2019
Chromosome 17q gains are a common alteration in high-risk neuroblastomas with unknown functional significance. We identified a 17q super-enhancer regulated T-box Transcription Factor 2 (TBX2) as constituent of a core regulatory circuitry driving ...
Bieke Decaesteker, Katleen De Preter, Frank Speleman   +2 more
doaj   +1 more source